Zydus to supply Sagent's Caffeine Citrate Oral Solution from Jarod, post USFDA's PAS Approval

Zydus Lifesciences's (Formerly known as Cadila Healthcare Ltd.), an innovation-led global lifesciences company announced that it will be manufacturing and supplying Sagent's Caffeine Citrate Oral Solution in the strength of 60 mg per 3 mL (20 mg per mL) Single-dose Vial (US RLD: CAFCIT) from its injectables facility at Jarod, Gujarat, India. The company announced that it received the Prior Approval Supplement (PAS) Approval from the US Food and Drug Administration (USFDA), which allows for a site transfer and manufacturing of the drug at Jarod.

This product is indicated for the short-term treatment of a breathing problem (Apnea) in premature infants. Caffeine blocks certain proteins (adenosine receptors) which leads to improved breathing in these infants.

Sagent Pharmaceuticals, Inc. (Sagent), a Nichi-Iko Group Company, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing pharmaceutical products for the North American market, with a specific emphasis on injectables.

Prior Approval Supplement (PAS)

A Prior Approval Supplement (PAS) is an application which seeks to make changes to an already approved application, such as an Abbreviated New Drug Application (ANDA), which is used by the USFDA to approve generic drugs.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 363.10 as compared to the previous close of Rs. 371.85. The total number of shares traded during the day was 28066 in over 1007 trades.

The stock hit an intraday high of Rs. 374.70 and intraday low of 362.00. The net turnover during the day was Rs. 10248527.00.

Source : Equity Bulls

Keywords

CadilaHealthcare INE010B01027 ZydusLifesciences Sagent CaffeineCitrate OralSolution InjectablesFacility